Effect of AIRVO Heated Humidification in Bronchiectasis

Who can take part

• Radiological evidence of bronchiectasis evaluated through a CT-scan of the chest
• Daily sputum production
• Presence of at least 3 exacerbations requiring antibiotic therapy during the 12 months prior randomization
• Absence of exacerbations during the 28 days prior randomization
• Having the bronchiectasis management/therapy optimized according to international guidelines (ERS Polverino 2017) during the 12 months preceding randomization and no changes in therapy occurred during the 28 days prior randomization
• Airways clearance physiotherapy optimized and unchanged during the 12 months prior randomization
• Being able to use myAIRVO2 (assessed by study investigators)
• Given consent to inclusion in the study

Who cannot take part

• Being enrolled in other intervention trials during the 12 months prior randomization
• Active smoker or ex-smoker who underwent smoking cessation during the 4 weeks prior randomization
• Any other disease or medical condition diagnosed during the 3 months prior randomization which can affect patients' safety
• Long-term treatment with non-invasive ventilation (NIV)
• Long-term night treatment with continuous positive airway pressure (CPAP)
• Major haemoptysis (more than 300ml or requiring embolization or requiring blood transfusion) during the 6 weeks prior randomization
• Use of drugs that can modify mucus liquid content including mannitol, Hypertoinc saline, DNase, NAC
• Changes in the rehabilitation/respiratory therapy program during the 28 days before randomization
• COPD or asthma recognized as main diseases by the study investigator
• Lung cancer in the last 5 years
• Tracheostomy
• Cystic fibrosis
• Traction bronchiectasis in the context of pulmonary fibrosis
• Pregnant and brest-feeding women